Objectives To evaluate Hepatitis C virus (HCV) knowledge and awareness among pregnant women with opioid use disorder (OUD). Methods From May through November 2015, a one-time survey was distributed to a convenience sample of pregnant women with OUD to assess their knowledge and awareness of (a) risk factors for HCV infection, (b) HCV transmission prevention strategies, (c) hepatotoxic risk reduction and (d) perinatal transmission and neonatal implications of HCV infection. Chi square and Fisher's exact tests were used to compare demographic characteristics and HCV knowledge between participants who were HCV positive and negative. Results Of 179 pregnant women with OUD approached, 169 (94%) completed the survey. Of these, 153 (90.5%) reported at least one risk factor for HCV infection, 85 (50.3%) were HCV positive and 38 (44.7%) of HCV positive women were diagnosed with HCV for the first time during pregnancy. When HCV knowledge was evaluated, 114 (66.7%) responded that sharing eating utensils could transmit HCV, 69 (55.0%) responded that there is a vaccine to prevent HCV and 56 (32.7%) did not identify intranasal drug use as a risk factor for HCV transmission. Among HCV positive women, 61 (71.8%) associated breastfeeding with an increased risk for HCV transmission, 33 (38.1%) failed to identify the importance of pediatric follow-up for HCV-exposed children and 16 (18.8%) perceived the risk of HCV vertical transmission as "likely" or "very likely." Conclusions for Practice Gaps in HCV knowledge exist among a rapidly growing population of pregnant women with OUD. Healthcare providers have a unique opportunity to provide HCV education and counseling during pregnancy. What this study adds? Over 90% of pregnant women with OUD in our sample reported at least one risk factor for HCV infection. However, many pregnant women with OUD have a low level of knowledge regarding several HCV-related content areas including the impact of HCV infection during pregnancy on perinatal transmission, breastfeeding and the need for pediatric follow-up.
Introduction
Hepatitis C virus (HCV) infection has increased dramatically among young women because of the opioid epidemic. Between 2011 and 2014, the national prevalence of HCV infection among reproductive-aged women increased by 22% (Nelson et al. 2016) . In rural Appalachian states where the prevalence and consequences of opioid abuse have been particularly alarming, the rate of HCV infection among young women has increased by 200% (Nelson et al. 2016) . Among young people with HCV, 73% report a history of injection drug use, which is now the primary risk factor for HCV infection in the United States (Moyer and Force 2013; Iqbal et al. 2015) .
Increasing rates of HCV infection among reproductiveaged women has led to a rise in the prevalence of HCV in pregnancy. Approximately 60-75% of pregnant women with a history of opioid abuse are HCV positive, with 63-72% reporting a history of injection drug use (Towers et al. 2016; . Vertical transmission occurs in approximately 5-6% of HCV RNA positive pregnancies and is the most common route of new infections in young children (Mohamoud et al. 2014) . Between 2011 and 2014, the number of infants born to HCV positive women in the United States increased by 68% and testing for HCV infection among young children increased by 14% (Nelson et al. 2016) .
Approximately 30-60% of women with opioid use disorder (OUD) are diagnosed with HCV for the very first time in pregnancy (Towers et al. 2016; . Enhanced engagement in health care services and a heightened investment in behavior change during pregnancy suggest that pregnancy is a critical period for HCV identification, evaluation and education among high-risk populations Prasad 2016) . Providers that care for pregnant women with OUD have a unique opportunity to provide education regarding HCV risk factors, transmission and screening (Burns and Minkoff 1999; Prasad and Honegger 2013) . Moreover, in the era of highly-effective direct-acting antiviral agents (DAAs), education regarding the enhanced tolerability and safety profile of these medications can facilitate enrollment in HCV treatment after delivery (Dieterich et al. 2015) .
Among an expanding population of pregnant women with OUD who are at high-risk for HCV infection, little is known about what women understand about HCV and the impact it may have on their pregnancy. Identification of patient knowledge gaps related to HCV is critical for the development of counseling interventions and infection prevention strategies to address one of the many consequences of the opioid epidemic. Therefore, the purpose of this study is to evaluate pregnant women with OUD's knowledge and awareness of (a) risk factors for HCV infection, (b) HCV transmission prevention strategies, (c) hepatotoxic risk reduction and (d) perinatal transmission and neonatal implications of HCV infection. Findings were also stratified by HCV infection status to determine if HCV knowledge and awareness differed among HCV negative and HCV positive pregnant women.
Materials and Methods
From May through November 2015, a one-time, deidentified survey was distributed to a convenience sample of 169 women with OUD. Pregnant women meeting DSM-5 criteria for OUD were approached by clinical staff to determine interest in study participation. Interested patients were approached by research staff and informed consent was obtained. The survey was self-administered on an electronic tablet during either an outpatient prenatal care visit, a hospital admission during pregnancy for conversion to mediation-assisted treatment (MAT) or an inpatient admission for obstetric delivery at our institution. Our institution is a free-standing women's hospital which provides obstetric care services to over 10,000 women each year. The survey took approximately 10 min to complete and participants received a $5 gift card for completing the survey. The study was approved by the University of Pittsburgh, Institutional Review Board (IRB) #PRO13100076.
The survey was designed using Qualtrics Survey Software© and consisted of 23 questions plus an additional 15 questions that were contingent on participant's answers. Questions included an assessment of demographic information, including age, race/ethnicity, marital status, education level, medical insurance, employment status, and living arrangements. HCV knowledge was evaluated across five domains: (1) general HCV knowledge, (2) neonatal HCV knowledge, (3) risk factors for HCV infection, (4) prevention of HCV transmission, (5) hepatotoxic risk factors and (6) perinatal HCV transmission risk (during pregnancy and while breastfeeding). Survey questions were derived from the National Health and Nutrition Examination Survey (NHANES) Hepatitis C Follow-up Survey, 2003 (Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS) [2003] [2004] [2005] [2006] [2007] [2008] , the US Preventative Services Task Force recommendations for HCV screening (Moyer and Force 2013) and the patient education about Hepatitis C (PEAHC) survey which collects baseline knowledge of HCV infection risk factors, transmission and behaviors (Straits-Troster et al. 2009; Arnold et al. 2016) . Questions regarding HCV transmission risk during pregnancy and breastfeeding and the need for neonatal follow-up were designed by the authors.
Hepatitis C virus infection status was defined by the participant's answer to the question, "Have you been diagnosed with Hepatitis C?" HCV positive status was defined by answering "yes" to this question and HCV negative status was defined by answering "no" or "don't know" to this question. The responses to HCV knowledge questions were either true/false or yes/no/don't know. To provide consistency in the presentation of responses in Table 2 , survey questions with "yes" responses were reported as "true" and survey questions with "no" or "don't know" responses were recorded as "false."
Descriptive statistics were generated to summarize all variables. Percentages reported reflect the proportion of responses to each survey question. Missing values were excluded from the analysis and all survey questions had less than 3% missing responses. Chi square tests were used to compare demographic characteristics and HCV knowledge between participants who were HCV positive and negative. When cell counts were < 5, Fisher's exact test was used. All analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC). A p value of < 0.05 was considered statistically significant.
Results

Sample Characteristics
Of 179 pregnant women with OUD approached, 169 (94%) completed the survey. Demographic characteristics of the sample are described in Table 1 . The majority of participants were between the ages of 25 and 29 years old, Caucasian, single, reported a high school or GED equivalent education, received medical assistance and were unemployed. Less than 10% of participants owned their own home and 5% reported that they were homeless. Over 95% of participants were currently being treated for OUD with opioid pharmacotherapy (methadone or buprenorphine).
Hepatitis C virus characteristics of the sample are described in Table 1 . The majority of participants were aware of HCV, had been tested for HCV and approximately 50% reported that they had ever been diagnosed with HCV. Among HCV positive participants (n = 85), 44% had been diagnosed for the first time during pregnancy. Regarding HCV treatment, 40% had seen a healthcare provider about HCV and 7% had been treated for HCV.
Risk Factors for HCV Infection
Risk factors for HCV infection among participants are described in Fig. 1 . Over 90% of participants reported at least one risk factor for HCV infection and the most common reported risk factors were past or current intravenous drug use (74.0%) and intranasal drug use (61.0%). Less than one-third of participants reported a history of incarceration, receiving an unregulated tattoo and having a sexual partner infected with HCV. Less than 10% of participants did not report any risk factors for HCV infection. Screening rates for HCV also differed by HCV risk factors. Among women who only reported a history of intranasal opioid use, 65.4% received testing for HCV versus 93.6% of women who reported a history of intravenous opioid use (p < 0.01).
HCV Knowledge
In Table 2 , HCV knowledge is presented as the proportion of participants who gave the correct responses to survey questions. When general and neonatal HCV knowledge was evaluated, less than half of participants correctly responded that there is not a vaccine to prevent HCV infection and two-thirds correctly responded that a baby born to an HCV positive mother needed to be evaluated by a pediatrician. The majority of participants correctly responded that injection drug use, unregulated tattoos, blood transfusion prior to 1992, sexual activity with multiple partners and snorting were risk factors for HCV infection. Regarding HCV transmission prevention, most participants correctly responded that a person should not share any injection drug equipment, cover cuts and sores, wear condoms, not share razors or toothbrushes, limit the number of sexual partners, and not donate blood, organs or semen to stop the spread of HCV. However, one-third of participants correctly responded that sharing eating utensils does not transmit HCV. Finally, when knowledge regarding hepatotoxic risk reduction strategies was evaluated, the majority of participants correctly responded that a person with HCV should not use injection drugs, drink alcohol, use Tylenol in excess and ask their doctor before starting any medications to decrease the risk of liver damage. However, less than half of participants knew that patients with HCV should receive a Hepatitis A vaccine.
Responses were stratified by HCV infection status to account for any differences in knowledge by HCV infection status. HCV positive participants were significantly more likely to correctly respond that HCV can be treated with medication (95.1% vs 78.8%; p < 0.01), that HCV is not transmitted by playing with a child (97.6% vs 86.7%; p < 0.01) or coughing (90.6% vs 75.9%; p = 0.01), that razors and toothbrushes should not be shared (100% vs 91.7%; p < 0.01),that Tylenol should not be used in excess (68.2% vs 53.6%; p = 0.05) and that HCV positive patients should get the Hepatitis A vaccine (55.3% vs 38.1%; p = 0.03). 
Knowledge of Perinatal HCV Transmission Risk
Among HCV positive participants (n = 85), the perceived likelihood of HCV transmission during pregnancy and while breastfeeding was evaluated on a 6-point Likert scale (Fig. 2) . While approximately half of participants responded that the likelihood of transmission during pregnancy was "little", 25.9% of participants responded "somewhat," 15.3% responded "likely," 3.5% responded "very likely" and 2.6% responded "none." While one-third of participants correctly responded that there was no risk of HCV transmission with breastfeeding, 36.5% responded "little," 21.2% responded "somewhat," 11.8% responded "likely" and 2.6% responded "definitely."
Discussion
Our findings identified multiple knowledge gaps related to HCV infection among pregnant women with OUD. Over 90% of women in our sample reported at least one risk factor for HCV infection, over 50% identified themselves as HCV positive and 44% of women reported that they were diagnosed with HCV during pregnancy. While almost all women indicated that they had heard of and been tested for HCV, many had a low level of knowledge regarding several HCV-related content areas. Knowledge gaps were also significantly greater among HCV negative versus HCV positive patients, which likely reflects an increase in provider counseling and education at the time of HCV diagnosis versus screening.
The majority of our sample incorrectly believed that there is a vaccine available to prevent HCV infection and had a poor understanding of the importance of the Hepatitis A vaccine for persons with HCV infection. Limited knowledge regarding hepatitis vaccinations may explain low Hepatitis A and Hepatitis B vaccination rates in pregnant and non-pregnant drug-using populations. In an investigation of hepatitis knowledge among active injection drug users at a syringe exchange program, only 8% of participants reported receiving the hepatitis A vaccine and only 11% reported receiving the Hepatitis B vaccine (Perlman et al. 2005) . Likewise, in an evaluation of prenatal care services provided to pregnant women with OUD, only 10% had documentation in their prenatal record that they received the Hepatitis A vaccine . Immunizations for Hepatitis A and B can be safely administered during pregnancy and are recommended for all patients with a history of illicit drug use, especially those who have a history of injection drug use, who share drug paraphernalia and who have evidence of chronic liver disease (Centers for Disease Control and Prevention (CDC) 1998).
Many women were also unaware that intranasal drug use is a risk factor for HCV infection due to blood exposure from snorting paraphernalia. In a recent forensic analysis of drug snorting materials including straws, 24% of devices had evidence of human blood (Towers et al. 2016) and HCV RNA has also been isolated in the nasal secretions of HCVinfected patients and on their snorting straws (McMahon . Over 60% of our sample reported a history of intranasal drug use which emphasizes the high prevalence of this route of drug use and the importance of HCV screening when intranasal use is identified (Prasad 2016) . Hepatotoxic risk reduction strategies were also poorly understood by pregnant women in our sample. Over 30% of HCV positive participants were not aware that Tylenol should not be used in excess and that care should be taken prior to initiating any new medications. Significant gaps in HCV knowledge have also been demonstrated among non-pregnant drug Variations in the sample sizes listed in the tables compared to the overall response rate is due to missing values for those particular questions, less than 3% missing for all responses, n (%) unless otherwise specified a p Values were obtained from Chi square tests, when cell counts were < 5, Fisher's exact test was used b Persons with HCV infection and more than one partner should protect their partners against HCV acquisition by using male latex condoms (Workowski and Bolan 2015) 2007; Day et al. 2008; North et al. 2013 ). Unique to this study, HCV perinatal transmission knowledge was also evaluated. Vertical transmission of HCV occurs in approximately 5-7% of pregnancies (Fraquelli et al. 2000; Azzari et al. 2002; Mohamoud et al. 2014) . In this study, approximately 18% of HCV positive women responded that vertical transmission was "likely," or "very likely." These results suggest that HCV positive women may overestimate the risk of vertical transmission and could benefit from informed discussions during pregnancy to rectify actual versus perceived risk. Likewise, over two-thirds of participants associated a risk of HCV transmission with breastfeeding. In a systematic review conducted by the US Preventative Services Task Force, no association was found between breastfeeding and HCV transmission in over 14 cohort studies (Chou et al. 2013 ). Breastfeeding and breastmilk are critically important for opioid-exposed infants due to associations with reduced NAS severity, greater maternal confidence and enhanced mother-infant bonding (Young et al. 2009; Murphy-Oikonen et al. 2011; Paul et al. 2012; Collett et al. 2013; Skurtveit et al. 2013) . As a result, prenatal care providers should encourage all women with OUD and HCV to breastfeed and caution should only be exercised if a patient develops an open or bloody lesion on her nipples or breast (Bogen et al. 2014) .
Finally, only 62% of HCV positive participants responded that infants born to HCV positive mothers must be tested by a pediatrician. These results are consistent with reports that HCV testing rates for perinatally exposed children are alarmingly inadequate (Maxwell et al. 2014) . In an evaluation of pediatric testing rates for children born to over 500 HCV positive women in the Philadelphia Hepatitis Registry, only 16% of HCV-exposed children were tested for HCV (Newbern et al. 2016) . Likewise, from 2000 to 2009, only 12% of HCV-exposed children in Florida received HCV testing and only 1.6% of HCV antibody positive children were actively followed by a pediatric gastroenterologist (Smith et al. 2012) . The American Academy of Pediatrics (AAP) and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) recommend HCV antibody screening for all children born to HCV positive women at 18 months (American Academy of Pediatrics (AAP) 2012; . Positive HCV antibody screening should be followed by confirmatory HCV RNA testing to identify chronic pediatric HCV infection (American Academy of Pediatrics (AAP) 2012; .
HCV screening, education and counseling is critical for drug using populations because awareness of infection status and knowledge of risk factors for infection and transmission is correlated with behavior. In our sample, 87% of women reported that they had been tested for HCV which is consistent with previously reported HCV screening rates of 77-98% in high-risk populations during pregnancy (Leslie et al. 2008; Liu 2009; . Women with only a history of intranasal opioid use were also significantly less likely to be screened for HCV than women with a history of intravenous opioid use (65.4% vs 93.6%; p < 0.01) which demonstrates a need to increase provider awareness of risk factors that should prompt HCV screening. Persons who are unaware of their HCV status are significantly more likely to share needles and other drug paraphernalia (Corsi et al. 2002) and persons with greater HCV-related knowledge are more likely to engage in HCV treatment. In an evaluation of 320 patients on methadone maintenance therapy, greater HCV knowledge was independently associated with an increased willingness to be treated for HCV (OR 1.76, 95% CI 1.06-2.92) (Dimova et al. 2014) . Among HCV positive pregnant women in our sample, only 40% had seen a doctor about their HCV and only 7% responded that they had engaged in HCV treatment.
The study has several limitations. The study was based on a convenience sample of pregnant women with OUD and our findings may be subject to selection and response bias. The study sample is also representative of patients at an urban, academic medical center and their responses may differ from responses of patient populations cared for in rural areas or in community hospital settings. Likewise, over 95% of our sample were using MAT and their responses may have differed from the responses of patients who were not engaged in OUD treatment. Moreover, the participants in our sample were predominantly Caucasian and their responses may not be generalizable to other minority populations. HCV infection status was based on the self-report of the women surveyed and the actual HCV serostatus of participants was unknown. However, in an evaluation of concordance between self-reported and actual HCV infection among intravenous drug users, 80% of subjects accurately reported their HCV infection status. (Aitken et al. 2013 ) Approximately 17% of participants were unsure of their HCV infection status which could also have contributed to an inaccurate representation of the true prevalence of HCV infection in our sample. Finally, questions from our survey may have been interpreted differently and not all participants may have been honest in their responses.
Conclusions
Our study identified multiple gaps in HCV knowledge among a rapidly growing population of pregnant women with OUD and highlights the need to provide further patient and provider education regarding risk factors for HCV infection and transmission. Prenatal care and substance abuse treatment providers often play a critical role as gatekeepers to health care services for vulnerable, high-risk patient populations such as pregnant women with OUD and have a unique opportunity provide HCV education and counseling during pregnancy and linkage to HCV treatment providers following delivery.
